Michigan late-stage biopharma, Sling Therapeutics, said a Phase IIb/III LIDS trial of its oral small molecule therapy designed to treat thyroid eye disease (TED) met its primary endpoint.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback